Loading stock data…
QNRX
$4.95+0.38 (+8.32%)
After Hours$4.97+0.02 (+0.40%)· Last close Jun 9
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Quoin Pharmaceuticals, Ltd. in the Healthcare sector is trading at $4.95. Wall Street consensus targets $29.75 (4 analysts), implying a +501.0% move over the next 12 months. The stock is currently near its 52-week low of $4.11, remaining 47.9% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +501.0% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$4.95
Potential Downside
0%
Whystock Fair Value$4.95
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Mean target$29.75+501.0%
Range$14.00 – $40.00
Fundamentals
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lo...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-193.66%
Volume
Today's trading volume
27,385
Recent News
Quoin Pharmaceuticals Insider Ups Holding By 1,515,200% During Year
Looking at Quoin Pharmaceuticals, Ltd.'s ( NASDAQ:QNRX ) insider transactions over the last year, we can see that...
Top Midday Gainers
Quoin Pharmaceuticals (QNRX) shares soared 126% amid heavy trading intraday after the company said F
Quoin Pharmaceuticals Shares Jump After Announcing $104.5 Million Private Placement
Quoin Pharmaceuticals (QNRX) shares jumped nearly 170% in recent Friday trading after the company sa